We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00419484
Recruitment Status : Completed
First Posted : January 8, 2007
Last Update Posted : January 8, 2007
Information provided by:
Dokkyo Medical University

Brief Summary:
We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Hypertension Dyslipidemia Diabetic Nephropathy Drug: pioglitazone Phase 4

Detailed Description:

Primary composite endpoints:

Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine)

Secondary endpoints:

urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout

Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Study Start Date : March 2004
Estimated Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • type 2 diabetes HbA1c: more than 7% and less than 9%

Exclusion Criteria:

  • insulin treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00419484

Dokkyo Medical University, Koshigaya Hospital
Koshigaya, Saitama, Japan, 343-8555
Sponsors and Collaborators
Dokkyo Medical University
Principal Investigator: Yoshimasa Aso, MD Dokkyo Medical University, Koshigaya Hospital

ClinicalTrials.gov Identifier: NCT00419484     History of Changes
Other Study ID Numbers: 0309
First Posted: January 8, 2007    Key Record Dates
Last Update Posted: January 8, 2007
Last Verified: January 2007

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders
Kidney Diseases
Urologic Diseases
Diabetes Complications
Hypoglycemic Agents
Physiological Effects of Drugs